• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Recommends Guidelines for Clinical Research of Cannabis Drugs

FDA Recommends Guidelines for Clinical Research of Cannabis Drugs

July 27, 2020

Clinical research on human drugs that contain cannabis can be conducted legally as long as the amount of the substance in the investigational product is within limits set by a new FDA draft guidance.

Cannabis-derived products can be used in human trials as long as the products contain less than 0.3 percent delta-9 tetrahydrocannabinol (THC). The guidance suggests that investigators calculate the level of delta-9 THC in their proposed product early in the development process to gain insight into potential control status of the product.

The FDA also recommends that sponsors provide quantitative data indicating the amount of THC in their products and detailed descriptions of testing methods used to evaluate THC levels.

In addition, the guidance states that cannabis is held to the same regulatory standards as any other botanical product and suggests ensuring batch-to-batch consistency of products via a chemical fingerprint.

Currently, there is only one FDA-approved product that uses a cannabis extract. GW Pharmaceuticals’ Epidiolex was approved in 2018 for seizures related to Lennox-Gastaut syndrome and Dravet syndrome.

Read the full guidance here: https://bit.ly/2WTf8U1.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing